Suissa S, Ernst P
Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Québec, Canada.
Eur Respir J. 2003 Jan;21(1):101-4. doi: 10.1183/09031936.03.00058503.
Asthma treatment guidelines were introduced in Japan in the 1990s, insisting as elsewhere, on the importance of anti-inflammatory therapy. The present study assessed whether use of anti-inflammatory medications was associated with a decrease in asthma mortality in Japan, the first country to use leukotriene receptor antagonists. A population-based ecological study was conducted, spanning the period 1987-1999, among people aged 5-34 yrs in Japan. The association between the yearly rate of asthma death and sales of inhaled corticosteroids and leukotriene receptor antagonists was estimated using Poisson regression. The yearly asthma death rate was stable at 6-7 deaths per million before the introduction of leukotriene receptor antagonists in 1995 and decreased by 23% thereafter, reaching 3.5 per million in 1999. The rate of asthma death was found to decrease with increasing use of both leukotriene receptor antagonists and inhaled corticosteroids. The rate ratio of asthma death was 0.96 per 1 million 25-day treatment courses of inhaled corticosteroids and 0.80 for every 1 million 25-day treatment courses of leukotriene receptor antagonists, consumed per year in Japan. The increasing use of inhaled corticosteroids and leukotriene receptor antagonists may have contributed to the significant reduction in asthma mortality among young asthmatics in Japan.
哮喘治疗指南于20世纪90年代在日本推行,与其他地方一样,强调抗炎治疗的重要性。本研究评估了在首个使用白三烯受体拮抗剂的日本,使用抗炎药物是否与哮喘死亡率降低相关。我们开展了一项基于人群的生态学研究,研究对象为1987年至1999年期间日本5至34岁的人群。使用泊松回归法估算了哮喘年死亡率与吸入性糖皮质激素及白三烯受体拮抗剂销量之间的关联。在1995年引入白三烯受体拮抗剂之前,哮喘年死亡率稳定在每百万人口6至7例死亡,此后下降了23%,1999年降至每百万人口3.5例。研究发现,随着白三烯受体拮抗剂和吸入性糖皮质激素使用量的增加,哮喘死亡率降低。在日本,每年每使用100万个25天疗程的吸入性糖皮质激素,哮喘死亡的率比为0.96;每年每使用100万个25天疗程的白三烯受体拮抗剂,哮喘死亡的率比为0.80。吸入性糖皮质激素和白三烯受体拮抗剂使用量的增加,可能是日本年轻哮喘患者哮喘死亡率显著降低的原因。